Navigation Links
ASH international clinical collaboration replicates high cure rate of APL in developing countries
Date:1/14/2013

n the IC-APL registry study conducted in Brazil, Chile, Mexico, and Uruguay compared to regimens used in trials in developed countries was the replacement of the commonly used anthracycline idarubicin with the less expensive and more readily available drug daunorubicin. Patients enrolled in the trial received combination therapy including oral ATRA in two daily doses until complete remission and daunorubicin given intravenously on days 2, 4, 6, and 8. Throughout the trial, participating sites registered all cases using common clinical record forms in the Pediatric Oncology Network Database (POND) and collaborated with national clinical trial coordinators and reference laboratories to confirm the integrity and accuracy of treatment data.

After approximately three years of follow-up, investigators observed incredibly promising results: 80 percent of patients achieved two-year OS and 91 percent achieved DFS, all with a low cumulative incidence of relapse (4.5%). Early patient mortality (death occurring between diagnosis and first evaluation at 30 days) in the trial was reduced by nearly half compared to historical controls, and overall survival improved by 30 percent. Of the 180 evaluable patients that participated in the four host countries, 153 (85%) achieved complete remission.

After five years of follow-up, 75.4 percent of all patients enrolled and 90.2 percent of those who achieved CR remained alive. Early death occurred in 27 patients (15%). These rates of death are considerably lower than other population-based studies analyzing early mortality of APL patients conducted in the United States and Sweden (17.3% and 29%, respectively), further demonstrating the safety of this treatment combination. The most frequent hematologic toxicity was grade 4 neutropenia (low neutrophil count), which was observed in a small group (3.3%) of patients. No significant toxicities were reported during maintenance therapy and no secondary malignancies were reporte
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Marketing Xocolate International Corporation (MXI Corp) Launches “The Whole Story” World Tour To Highlight Xocai Healthy Chocolate Product, Full-Line Up of Guest Speakers
2. Okuyamba Named Official Selection in Long Island International Film Festival
3. NEBOSH International Diploma and Certificate Programs Now Offered in the USA by the Only USA Based Accredited Provider - NEBOSH IOG February 18-22, 2013
4. Worldwide Power Products Launches Agent Program to Reach International Customers; Hires Director of Latin American Operations
5. Kids Matter International Celebrates a Night of Glam and Giving Rio Style
6. International Essential Tremor Foundation Awards Scholarship
7. Xoçai™ Activ, A Delicious, Healthy, Active-lifestyle Antioxidant Beverage Has Been Released by Marketing Xocolate International Corporation (MXI Corp)
8. Marketing Xocolate International Corporation (MXI Corp) Unveils New Healthy Dark Chocolate Product: Xoçai™ Nuggets, Which Are Both Diabetic And Vegan Friendly
9. Marketing Xocolate International Corporation (MXI-Corp) Introduces Xe Healthy Energy Drink, A Rich And Delicious Antioxidant Beverage, Now Added to Xoçai™ Product Line
10. The Stone Bake Oven Company: UK Wood Fired Ovens Are Coming Up Trumps Over International Competitors
11. Marketing Xocolate International Corporation Sponsors The Xo-Love Project, An International Humanitarian Effort, to Increase Charitable Donations And Community Outreach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July ... HIV who was thought to be cured by immediate and ... levels of the AIDS-causing virus in her bloodstream, disappointed federal ... years old, had remained virus-free even though she stopped taking ... hoped her remission would open the door to a functional ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and segments ... revenue forecast. The well intervention services market in Europe is ... $3.4 billion by 2018, at a CAGR of 7% from ... Europe Well Intervention Market report, to get an idea of ... the segmentation in the Europe well intervention market, and is ...
(Date:7/11/2014)... (HealthDay News) -- Children who have emergency surgery ... and potentially even death than those who have ... However, the Johns Hopkins researchers noted that the ... analyzed data on nearly 440,000 simple emergency surgeries ... a 22-year period. The surgeries are considered ...
(Date:7/11/2014)... According to a new market research ... Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application ... Transportation, Agriculture) & Geography - Global Trends & Forecasts ... Things market was worth $1029.5 Billion in 2013, and ... an estimated CAGR of 4.08% from 2014 to 2020. ...
(Date:7/11/2014)... Researchers from The Miriam Hospital have found that ... significantly higher rates of smoking than those without ... less likely to attempt quitting than those without ... be sufficient for this population. The study and ... print in the American Journal of Public ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Miriam Hospital study examines smoking prevalence 2
... -- The rising prevalence of obesity around the globe ... on healthcare systems and on overall economies. A major ... these burdens to inform public policies. Using a ... consequences from rising obesity rates in the United States ...
... , FRIDAY, Aug. 26 (HealthDay News) -- Scientists ... most common noncancerous tumors in women of childbearing age. ... discomfort, occur in 60 percent of women by the age ... the most common reason for hysterectomy. Despite their importance, ...
... THURSDAY, Aug. 25 (HealthDay News) -- A new scoring system might ... how much time they have left so they can prepare for ... in Palliative Care Study (PiPS) predictor model, the scoring system plugs ... or months a person with advanced cancer most likely has to ...
... People with lower socioeconomic status are much more likely to ... educated, according to a recent UC Davis study. Published online ... that this risk persists even with long-term progress in addressing ... elevated cholesterol. "Being poor or having less than ...
... , THURSDAY, Aug. 25 (HealthDay News) -- One of the ... was the secrecy that shrouded products he was about to ... iPad -- creating tremendous consumer interest. Jobs, announcement Wednesday ... the hugely successful technology company he co-founded in a northern ...
... News) -- The number of obese people in the United States ... 2030, and the number of obese people in the United Kingdom ... predicts. Obesity-related diseases and health care costs will soar as ... The Lancet . Already, the U.S. and U.K. obesity rates ...
Cached Medicine News:Health News:65 million more obese adults in the US and 11 million more in the UK expected by 2030 2Health News:65 million more obese adults in the US and 11 million more in the UK expected by 2030 3Health News:Scoring System May Tell the Dying How Long They Have to Live 2Health News:Lower socioeconomic status linked with heart disease despite improvements in other risk factor 2Health News:Steve Jobs Faces Uphill Battle Against Cancer: Experts 2Health News:Steve Jobs Faces Uphill Battle Against Cancer: Experts 3Health News:Obesity Continues to Balloon in U.S. and U.K.: Study 2
(Date:7/10/2014)... 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... analog IC solutions, today announced that it will host ... at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) ... 2014 third quarter ended June 30, 2014. ... before 6:50 a.m. Pacific time on July 24, 2014.  ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... REGN ) today announced results from the Phase ... Trap) for the second-line treatment of non-small cell lung ... the chemotherapy drug docetaxel did not meet the pre-specified ...
... Nephros, Inc. (OTC Bulletin Board: NEPH ), ... for therapeutic applications, infection control, and water purification, today ... placement that together resulted in gross proceeds of approximately ... by Nephros from the rights offering and private placement ...
Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 2Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 3Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: